VPPN Localisation Series: Webinar 1 - What to consider for local vaccine manufacturing? - 20 May 2025, 10am GMT+2
Link to register for the webinar
Dear TechNet members,
We are all talking about localising the production and procurement of immunisation supplies. The disparity of the distribution of immunisation supplies associated with manufacturing capacity has indeed stood out globally, since the outbreak of the COVID-19 pandemic. Producing vaccines locally may offer increased autonomy and improved vaccine security, but requires skilled technicians, stringent regulatory oversight and lengthy timelines. Governments also need a deep understanding of markets, demand and supply levers, regulatory requirements and manufacturing processes to initiate and/ or scale local immunisation supplies procurement.
To better understand the challenges of localisation and learn from peers who have chosen to manufacture vaccines locally, join us on Tuesday, 20 May, at 10am GMT+2, for the first webinar in this new VPPN series. The event will focus on local vaccine manufacturing, thanks to the contributions of government partners from Egypt and South Africa and the expertise of the Clinton Health Access Initiative (CHAI).
The webinar will be held in English, Arabic, French and Russian and take place on Zoom, on Tuesday, 20 May 2025, from 10am to 11.05am GMT+2.
To take part in it, you need to register here. Please, note that registration is compulsory and that, once registered, you will receive an e-mail confirmation with the link to the webinar.
Are you also planning to manufacture vaccines? Do not hesitate to share any question or concern you have on the subject in the Comments section below, at the bottom of the page. A 15-minute Q&A session will be included in the webinar, and our panellists and experts will be happy to answer you with their experience and insight.
Please find below all relevant details on this webinar and the whole series.
We are looking forward to welcoming you during this event. And in the meantime, you can reach me, through the platform or by email at [email protected], for any request or question you might have.
Kind regards,
Dyuti
*****
Objectives
- Outline the historical and emerging objectives of local vaccine manufacturing
- Provide an overview of the key components needed to create an enabling environment for local vaccine manufacturing
- Discuss key common challenges faced with countries when creating the enabling environment, and share respective experiences and lessons learned
- Answer questions on the topic
Speakers
Subject-matter expert:
• Mohammed Badat, Senior Associate, Vaccine Markets, Clinton Health Access Initiative (CHAI)
Egypt:
• Mostafa Ghorab, Business Development Director, The Egyptian Authority for Unified Procurement
• Rania Mohsen, Project Management Department Director, The Egyptian Authority for Unified Procurement
South Africa:
• Marione Schonfeldt, Senior Pharmaceutical Policy Specialist, National Department of Health
Moderator:
• Kristina Lorenson, Senior Contracts Manager, Vaccine Centre, UNICEF
Agenda
10:00am GMT+2 Welcome and introduction of the topic
10:03am GMT+2 CHAI presentation
10:18am GMT+2 Egypt's presentation
10:33am GMT+2 South Africa's presentation
10:48am GMT+2 Questions & Answers
11:03am GMT+2 Closing remarks
When setting up local vaccine manufacturing, here are the key points to consider:
1. Regulatory approval: The country must have a strong regulatory authority to approve, inspect, and monitor vaccine production for safety and quality.
2. Technology and expertise: Manufacturing vaccines needs advanced technology and trained professionals in microbiology, biotechnology, and quality control.
3. Infrastructure: Facilities must meet strict standards, including clean rooms, quality testing labs, storage areas, and equipment for sterilization.
4. Raw materials and supply chain: Reliable sources of raw materials, chemicals, packaging, and cold chain systems are essential.
5. Funding: Large investment is needed for construction, equipment, skilled staff, and maintaining production quality.
6. Research and development (R&D): A strong R&D base helps to improve vaccines, adapt to new diseases, and respond to outbreaks.
7. Partnerships: Working with global vaccine makers, universities, or organizations can help with knowledge transfer and technical support.
8. Workforce training: Staff need regular training to handle vaccines safely, follow production protocols, and use advanced equipment.
9. Quality control and assurance: Each batch must be tested for effectiveness, safety, and contamination before release.
10. Market and demand: There should be a clear demand for vaccines locally or regionally to make the business sustainable.
11. Intellectual property (IP) rights: IP agreements may be needed if using technology developed by other companies.
12. Government support: Policies, subsidies, or tax incentives can help reduce costs and encourage investment.
13. Public trust: People need to trust locally made vaccines, so transparency, safety, and communication are important.
Regards
REMINDER
UNICEF VPPN WEBINAR - LOCALISATION SERIES
What to consider for local vaccine manufacturing?
🔗 Register here: https://unicef.zoom.us/webinar/register/WN_ZHmyGjZbRmWVlnWKr9LePA
📆 Date: Tuesday, 20 May 2025
🕙 Time: 10:00–11:05 am (GMT+2)
🌐 Languages: English, Arabic, French, Russian
📍 Platform: Zoom
Register and join us on Tuesday, 20 May, at 10am GMT+2, for the first webinar in our new VPPN series on localisation, to better understand the challenges of manufacturing vaccines locally and learn from peers who have chosen to implement a local production strategy! Government partners from Egypt and South Africa as well as an expert from the Clinton Health Access Initiative (CHAI) will share their experience, knowledge and lessons learnt with you.
Find all relevant details in the above post!
We are looking forward to seeing you at this event, which promises to be enriching and insightful.
- Page :
- 1